The global healthcare industry is getting attention from investors as specialised medical technology companies look for ways to get money through public markets. Even though there is uncertainty in markets healthcare businesses with unique products, strong customer networks and good growth potential still get interest from big investors.
One big change is the public offering (IPO) of the Swiss dental healthcare company vVARDIS Holding AG, which has set the price of its US stock market offering at $18 per share raising $175 million in total money.
The company offered 9,722,223 Class A shares with its shares planned to start trading on the New York Stock Exchange (NYSE) on November 13 2026 under the ticker symbol VVVV. The offering is expected to finish around November 16 depending on closing conditions.
The IPO is a step for vVARDIS as it wants to grow its business make its finances stronger and make its dental technology products available in more countries.
The event also happens at a time for the healthcare IPO market. Other medical and biotechnology companies are trying to go public showing that investors still look at healthcare businesses even when the tech sector has problems.
Details of the $175 Million IPO
vVARDIS Holding said the pricing of its public offering happened on November 13 2026. The company set the price of 9.72 million Class A shares at $18 each making about $175 million in total money before the fees and other costs of the offering.
The offering has an option that lets the people handling the offering buy up to 1,458,333 more shares at the IPO price.
If that option is used fully it could add about another $26.25 million in money making the total possible value of the offering about $201.25 million.
The IPO is being handled by Goldman Sachs and J.P. Morgan as the people in charge. William Blair, UBS Investment Bank and Deutsche Bank Securities are also part of the team.
One thing to note is that the final IPO price of $18 is lower than the companys suggested price range of $21 to $24 per share.
The pricing process also had some changes in the number of shares offered. The company first planned to offer shares before deciding to reduce the number because of financial market changes. At the price the number of shares was increased to about 9.72 million while the price was set lower.
This outcome shows how important it is to balance the money the company wants to get with what investorsre willing to pay and the current market situation.
The shares are on the NYSE under the symbol VVVV giving people who invest in the stock market a chance to get involved with the medical technology business.
What Does vVARDIS Do?
vVARDIS was started in 2020 and is based in Zug, Switzerland. It works in the healthcare and medical technology area.
The company was created by sisters Dr. Haley Abivardi and Dr. Goly Abivardi, who are both dentists and business people.
Its business is about making -invasive treatments for early-stage tooth decay while keeping the natural tooth structure.
Usually treating cavities means taking out the damaged part of the tooth with a drill and filling it with a material. VVARDIS is trying to make a way using its own Curodont product line.
The companys technology uses formulas to help rebuild minerals in early-stage dental problems.
Its products are meant to help dentists stop tooth decay before it gets worse and needs intense treatment.
This method is important because finding and treating cavities early can help avoid serious dental work.
The company sells its products under the Curodont brand with versions for different places and uses.
Its main US product, Curodont Repair Fluoride Plus is sold as an over-the-counter drug under the US FDAs rules for treatments. The company also sells a version without fluoride, Curodont Repair in some countries as a device.
It is important to note that the FDA rules should not be confused with an approval for the product through a specific application.
Using this product approach vVARDIS wants to create a way of treating dental problems by focusing on early help and fixing the tooth naturally.
Curodont Product Adoption Supports Revenue Growth
One of the reasons investors are interested in vVARDIS is how much its Curodont products are being used.
Since starting its US business in January 2024 the company has made its products available in dental offices.
According to its paperwork its main Curodont products had been sold to than 20,000 of about 110,000 general dental offices in the US as of June 30 2026.
The company also said its products had been used on than 3.5 million teeth by that date.
The main US product had 112% sales growth for the nine months ending September 30 2026 showing business growth.
This growth is important because the dental field usually depends on ways of treatment the advice of professionals and long-term relationships between dental offices and suppliers.
Introducing tools needs training, trust from doctors and proof that the products can fit into the usual ways of working.
So getting dental offices to use its products could be a big advantage for vVARDIS.
The company still has a long way to go. Reaching dentists getting help from people who sell the products and showing that there is real demand for the products will be needed to keep growing.
Financial Performance: Revenue Expansion Alongside Operating Losses
The IPO happens as vVARDIS reports increases in revenue but still has big losses.
According to the companys paperwork total revenue was about $30.21 million in 2025 compared with $12.16 million in 2024.
That is 149% growth in revenue each year.
The company also did well in the half of 2026.
| Financial Metric | H1 2026 | H1 2025 |
|---|---:|---:|
| Net Revenue $28.56 million | $9.09 million |
| Gross Profit | $24.67 million $4.67 million |
| Operating Loss | $17.55 million | $24.08 million |
| Net Loss | $27.81 million | $32.06 million |
The first-half revenue increase shows more people want the companys products.
Its profit after taking out the cost of making the products also improved a lot reaching about 86.4% during the half of 2026.
The company had a big loss of about $56.45 million in 2025.
For the six months of 2026 the loss was still big at about $27.81 million.
These losses show the costs of selling, general and administrative work, research and development financing and growing the business.
The numbers show a point for investors: fast growth in sales does not always mean the company will make a profit.
As vVARDIS goes into the markets investors will be watching to see if its growing business can eventually make money and have positive cash flow.
How Will the Company Use Its IPO Proceeds?
Getting $175 million gives vVARDIS money to support its business plan.
The companys paperwork says that using the money for company purposes is the main plan.
These purposes include money for operations costs to run the company and buying things the company needs.
The company might also use some of the money for buying companies or investing in businesses, products, services or technologies that go with what it does.
It hasn't said it has any big deals or plans for buying other companies as part of this offering.
Having money could help the company grow its business make its products more available and support more development of its dental technology.
Expanding into countries is another possible use.
Dental treatment and rules are different in places. Entering areas needs partners to sell the products following the rules in that place training doctors and spending on marketing.
More money could help build these abilities while supporting more research and development.
How the company does with these plans will be important in seeing how much value the public listing creates.
Healthcare Companies Find Opportunities in the IPO Market
The vVARDIS offering is part of a movement of healthcare and biotechnology companies trying to get money from public stock markets.
Another big deal during the time was Windward Bio, a company based in Switzerland that makes treatments using antibodies for serious breathing and skin problems.
Windward Bio got about $175 million through its US IPO at $17 per share with its shares starting higher than the price it set when it first came out on Nasdaq on November 13.
These two deals show that companies in parts of healthcare are finding ways to get a lot of money even when there is uncertainty in the overall financial market.
Healthcare companies can have things that make them good investments compared to technology companies.
The need for treatments, health services and special products is affected by long-term health needs, new research and how people are changing in population.
This doesn't mean that healthcare IPOs are safe from market changes. Investors still look at how much the company's worth how fast it is growing, the risks from rules and the chance that the product might not work.
Companies with special products and clear chances to grow may still get investors even if other areas of the market are not doing well.
For healthcare companies going public can give them people to invest and a way to get more money in the future.
IPO Valuation and Investor Considerations
The price of vVARDIS at $18 per share below its suggested range of $21 to $24 shows how important it is to be careful with how much a company is worth.
Companies that want to go public must think about how investors see their chances to grow compared to their money.
For vVARDIS the growing business and how fast its products are being used are parts of the investment plan.
But the company has losses is not around very long as a business that sells dental technology and depends on other people to sell its products are all things that investors need to think about.
Another thing to consider is how the company is run.
The companys paperwork says it has a way of shares where some shares have voting power, than others.
After the IPO the two founders are expected to keep 87.6% of the total voting power assuming no one uses the option to buy more shares.
This structure allows the founders to keep a say in the companys decisions, including who gets on the board and big moves the company makes.
Founder control can help make sure the company follows a long-term plan. It also means that people who own shares in the company will not have much say in certain decisions.
Investors will therefore have to look at not how the company is growing but also how it is managed and how it uses money.
Distribution Networks Offer Both Things and Bad Things
A key thing that affects how vVARDIS does business is how much it depends on other companies to sell its products.
The companys SEC filing shows that Henry Schein made up 72% of its sales in 2025 and 70% in 2024.
Henry Schein is a seller of health and dental products, which gives vVARDIS access to well-known dental supply networks.
This partnership has helped Curodont products reach dental offices in the US.
Depending on one big customer has risks.
If orders go down if the way things are sold changes or if the special deal ends it could affect how available the products are and how money the company makes.
The deal with the distributor also has rules about prices and business terms that affect how flexible the company is.
Building partnerships with other sellers and talking more directly with dentists could help the company depend less on just a few sellers.
This will be very important as tries to grow around the world.
Rules and Competition Are Challenges
The dental technology business has a lot of chances to grow but it also has to deal with many rules.
Products used in work need to meet the rules, quality standards and safety requirements in different places.
If the way products are classified. If the things they can say about them change it could affect how the company sells them.
Competition is also a thing to think about.
Big companies that make products and new companies in health tech keep putting money into things like filling materials ways to prevent problems and digital tools for dentists.
vVARDIS has to show that its products are better than what's already out there.
It also needs to spend on teaching professionals and doing research to help people use its technology.
Another problem is turning interest in the products into people buying them over and over again.
Dentists need to trust how the products work have proof that they're good and know they can rely on them before using them every day.
So the companys future success will depend on keeping the products good while making more people buy them.
What Comes Next
Going public gives vVARDIS a chance to start a chapter in how the company grows.
Its main goals now are probably to get stronger in selling keep people using the products and invest more in research and development.
The company can also use its place in the market to get more attention from big investors companies that want to work with them and people who want to sell in other countries.
The companys current customers and growing sales give a base for growth especially in the US dental market.
Investors will pay more attention to making money how well the company uses its cash and if the sales keep growing.
The companys ability to cut down on losses while growing its business will be a sign of how well it is doing financially.
The overall situation in the healthcare IPO market will also be affected by interest rates how much the stock market is worth and how much people want to invest in medical tech companies.
If the market stays good other health companies may try to do the same to get money for growing and selling their products.
Conclusion
The $175 million IPO from vVARDIS Holding is a step in the growing dental medical technology field and shows more chances for health companies to get money from public markets.
The companys Curodont products, dentists using them and fast sales growth give a base for its plans in the public market.
But big losses depending much on one seller rules that must be followed and the founders having control are all important things to think about.
The IPO also happens at a time when health and biotech companies are also getting money showing that special medical businesses can still get support even when the whole market is uncertain.
Looking to the future vVARDIS needs to show that the money it raises can lead to business growth better money results and more people using its dental technology.
How it does, as a company that's public could give a good sign of how much investors want to support new health companies that have special products and new ways to treat patients.
Nexuswild welcomes factual corrections. Email contact@nexuswild.com with evidence and the article URL.
